Table 1 Baseline clinical characteristics and lipid profiles
|  | Total n = 208 | LDL-C status | ||
|---|---|---|---|---|
LDL-C controlled n = 75 | LDL-C uncontrolled n = 133 | p-value | ||
Age, years | 68(58.5,76) | 72(64.0,80.0) | 65(56.5,73.5) |  < 0.001 |
Male, n (%) | 135(64.9) | 50(66.7) | 85(63.9) | 0.689 |
BMI, kg/m2 | 24.5(22.8,26.6) | 24.7(22.9,26.8) | 24.3(22.8,26.6) | 0.625 |
Systolic BP, mmHg | 134(125,144) | 135.5(125,144) | 133(124,145) | 0.825 |
Diastolic BP, mmHg | 76(70,83) | 74(67,80) | 78(70,85) | 0.009 |
Hypertension, n (%) | 156(75) | 60(80) | 96(72.2) | 0.211 |
Smoking, n (%) | 68(32.7) | 22(29.3) | 46(34.6) | 0.438 |
CAD family history, n (%) | 30(14.4) | 12(16) | 18(13.5) | 0.627 |
ASCVD Risk Categories | Â | Â | Â | 0.378 |
 High risk, n (%) | 16(7.7) | 4(5.3) | 12(9.0) |  |
 Very high risk, n (%) | 158(76.0) | 61(81.3) | 97(72.9) |  |
 Extreme risk, n (%) | 34(16.3) | 10(13.3) | 24(18.0) |  |
Lipid profile at baseline (mmol/L) | ||||
 Total cholesterol | 4.14(3.43,4.92) | 3.73(3.16,4.24) | 4.31(3.64,5.20) |  < 0.001 |
 Triglyceride | 1.44(1.03,2.08) | 1.27(1.0,1.77) | 1.48(1.05,2.41) | 0.153 |
 HDL‑C | 1.18(0.95,1.45) | 1.18(0.92,1.44) | 1.19(0.95,1.46) | 0.512 |
 LDL‑C | 2.20(1.64,2.84) | 1.84(1.47,2.45) | 2.46(1.87,3.02) |  < 0.001 |
Glucose, mmol/L | 6.91(5.62,8.42) | 6.72(5.60,8.24) | 7.03(5.71,8.46) | 0.583 |
HbA1C, % | 6.9(6.2,7.8) | 6.90(6.30,7.60) | 6.90(6.20,8.00) | 0.908 |
Cre, μmol/L | 74.7(64.1,88.1) | 75.00(65.55,88.05) | 73.30(63.75,88.50) | 0.842 |
Lipid profile at follow-up (mmol/L) | ||||
 Total cholesterol | 3.76(3.21,4.56) | 2.90(2.56,3.32) | 4.28(3.73,4.92) |  < 0.001 |
 Triglyceride | 1.24(0.94,1.95) | 1.09(0.81,1.67) | 1.34(1.00,2.11) | 0.005 |
 HDL‑C | 1.18(0.94,1.42) | 1.07(0.88,1.38) | 1.24(0.96,1.44) | 0.107 |
 LDL‑C | 1.99(1.55,2.63) | 1.37(1.09,1.55) | 2.33(1.99,2.83) |  < 0.001 |
Glucose, mmol/L | 6.67(5.59,8.43) | 6.73(5.48,8.46) | 6.61(5.71,8.43) | 0.960 |
HbA1C, % | 6.8(6.2,7.8) | 7.00(6.20,7.63) | 6.70(6.25,7.80) | 0.945 |
Cre, μmol/L | 75.00(63.00,88.00) | 79.00(65.00,87.45) | 72.5(60.75,88.00) | 0.203 |
Anti-diabetic treatment | ||||
 Insulin, n (%) | 42(20.2) | 19(25.4) | 23(17.3) | 0.165 |
 Metformin, n (%) | 39(18.8) | 15(20) | 24(18.1) | 0.729 |
 Sulfonylurea, n (%) | 47(22.6) | 18(24) | 29(21.8) | 0.606 |
α-glucosidase inhibitor, n (%) | 66(31.7) | 29(38.7) | 37(27.8) | 0.137 |
Other, n (%) | 5(2.4) | 2(2.7) | 3(2.3) | 0.594 |
Non-drug, n (%) | 55(26.4) | 15(20) | 40(30.1) | 0.114 |
Aspirin/clopidogrel, n (%) | 110(52.8) | 46(61.3) | 64(48.1) | 0.067 |
Inter-scan period, year | 3.0(1.8,4.3) | 3.3(1.6,4.5) | 2.9(1.8,4.3) | 0.227 |